
Richard Blumenthal @SenBlumenthal
Jacking up the price of a lifesaving drug from $17.50 to $750 is brazen&unacceptable. As a result of Shkreli’s anticompetitive practices, patients lost out on generic Daraprim. The FTC was right to bring a case against Vyera for this price gouging behavior.https://t.co/u5Gty3sZ5G — PolitiTweet.org